GCG and type 2 diabetes mellitus: Initially developed for type 2 diabetes management, two incretin analogues have been approved that were previously indicated for diabetes management, namely liraglutide (Brand name ‘Saxenda’ produced by Novo Nordisk) and semaglutide (Brand name ‘Wegovy’ produced by Novo Nordisk).